Iovance Biotherapeutics (IOVA) Stock Price, News & Analysis

Company Overview

Iovance Biotherapeutics, Inc. is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes. This personalized approach aims to deliver a potent and durable anti‐tumor response, leveraging automated manufacturing processes developed in partnership with contract development and manufacturing organizations. The company’s clinical programs are supported by a comprehensive network of manufacturing sites and clinical trial locations across the United States and Europe.

Founded in 2007 as Lion Biotechnologies and rebranded to Iovance Biotherapeutics in 2017, the company is headquartered in San Carlos, California. Since its inception, Iovance has advanced its cell therapy technologies from early research through pivotal registration trials, collaborating with leading academic centers and regulatory agencies to refine its manufacturing and clinical processes. The company’s international footprint includes trial sites in North America, Europe and Latin America.

Iovance is led by a management team with extensive experience in oncology drug development and cell therapy commercialization. Maria Fardis, President and Chief Executive Officer, oversees strategic direction and operational execution, supported by senior leaders in clinical development, manufacturing and regulatory affairs. Together, the team seeks to bring transformational immunotherapies to patients with high‐unmet‐need solid tumors.

Key Stats

• Today's Range: $2.27 to $2.43
• 50-Day Range: $1.70 to $3.97
• 52-Week Range: $1.64 to $12.51
• Volume: 8.51 million shs
• Average Volume: 10.70 million shs
• Market Capitalization: $821.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.90
• Consensus Rating: Hold

Iovance Biotherapeutics Stock Analysis - MarketRank™

Iovance Biotherapeutics scored higher than 89% of companies evaluated by MarketBeat, and ranked 148th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Iovance Biotherapeutics has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 6 buy ratings, 7 hold ratings, and 1 sell rating.

Upside Potential

Iovance Biotherapeutics has a consensus price target of $11.90, representing about 424.2% upside from its current price of $2.27.

Amount of Analyst Coverage

Iovance Biotherapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($1.24) to ($0.88) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Iovance Biotherapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Iovance Biotherapeutics is -1.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Iovance Biotherapeutics has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.37% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently decreased by 0.06%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Iovance Biotherapeutics does not currently pay a dividend.

Dividend Growth

Iovance Biotherapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.12

Percentage of Shares Shorted

24.37% of the float of Iovance Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

Iovance Biotherapeutics has a short interest ratio ("days to cover") of 4.2.

Change versus previous month

Short interest in Iovance Biotherapeutics has recently decreased by 0.06%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 1.13

News Sentiment

Iovance Biotherapeutics has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Iovance Biotherapeutics this week, compared to 21 articles on an average week.

Search Interest

Only 50 people have searched for IOVA on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

MarketBeat Follows

Only 11 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -54% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.30% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

77.03% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

IOVA Stock Analysis - Frequently Asked Questions

How have IOVA shares performed this year?

Iovance Biotherapeutics' stock was trading at $7.40 at the start of the year. Since then, IOVA shares have decreased by 69.3% and is now trading at $2.27.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) announced its quarterly earnings results on Thursday, August, 7th. The biotechnology company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.04. The biotechnology company had revenue of $59.95 million for the quarter, compared to the consensus estimate of $67.14 million. Iovance Biotherapeutics had a negative trailing twelve-month return on equity of 52.87% and a negative net margin of 161.44%.
Read the conference call transcript.

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' top institutional shareholders include Geode Capital Management LLC (1.85%), Bank of America Corp DE (1.11%), Soleus Capital Management L.P. (0.90%) and Orion Investment Co (0.65%). Insiders that own company stock include Wayne P Rothbaum, Merrill A Mcpeak, Raj K Puri, Iain D Dukes, Ryan D Maynard and Frederick G Vogt.
View institutional ownership trends.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Iovance Biotherapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), CrowdStrike (CRWD) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/07/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IOVA
• CIK: 1425205
• Web: www.iovance.com
• Phone: (650) 260-7120
• Fax: N/A
• Employees: 500
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Iovance Biotherapeutics: $11.90
• High Price Target: $20.00
• Low Price Target: $2.00
• Potential Upside/Downside: +424.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.36
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$372.18 million
• Net Margins: -161.44%
• Pretax Margin: -161.36%
• Return on Equity: -52.87%
• Return on Assets: -41.31%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.27
• Quick Ratio: 2.89

Sales & Book Value

• Annual Sales: $164.07 million
• Price / Sales: 5.01
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.33 per share
• Price / Book: 0.97

Miscellaneous

• Outstanding Shares: 361,850,000
• Free Float: 324,583,000
• Market Cap: $821.40 million
• Optionable: Optionable
• Beta: 0.82